Form 8-K - Current report:
SEC Accession No. 0001437749-25-005802
Filing Date
2025-03-03
Accepted
2025-03-03 07:19:26
Documents
15
Period of Report
2025-03-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tgtx20250225_8k.htm   iXBRL 8-K 31821
2 EXHIBIT 99.1 ex_782107.htm EX-99.1 169063
  Complete submission text file 0001437749-25-005802.txt   354952

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tgtx-20250303.xsd EX-101.SCH 3408
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE tgtx-20250303_def.xml EX-101.DEF 11806
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tgtx-20250303_lab.xml EX-101.LAB 15857
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tgtx-20250303_pre.xml EX-101.PRE 12021
17 EXTRACTED XBRL INSTANCE DOCUMENT tgtx20250225_8k_htm.xml XML 2941
Mailing Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014
Business Address 2 GANSEVOORT STREET, 9TH FLOOR NEW YORK NY 10014 (212) 554-4484
TG THERAPEUTICS, INC. (Filer) CIK: 0001001316 (see all company filings)

EIN.: 363898269 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32639 | Film No.: 25693770
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)